26 August 2013 - Deborah Wilkes
Archived
Pharmstandard has paid US$590 million for Singapore's Bever Pharmaceutical, and moved a step closer to the planned spin-off of its branded OTC business.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.